Quarterly ResultMay 6, 2026, 02:49 PM
Cencora Q2 Net Income +128% to $1.64B; EPS $8.40; Acquires OneOncology
AI Summary
Cencora reported strong financial results for the three months ended March 31, 2026, with net income attributable to Cencora, Inc. more than doubling to $1.64 billion and diluted EPS reaching $8.40. Revenue increased to $78.36 billion. The company completed the acquisition of OneOncology for $7.39 billion in February 2026 and also classified its MWI Animal Health and U.S. Consulting Services businesses as held for sale, with the latter divested in April 2026.
Key Highlights
- Net income attributable to Cencora, Inc. for Q2 2026 rose 128.6% to $1.64 billion.
- Diluted EPS for Q2 2026 increased 128.3% to $8.40.
- Revenue for Q2 2026 grew 3.8% to $78.36 billion.
- Acquired majority equity interests in OneOncology for $7.39 billion on February 2, 2026.
- Declared cash dividends of $0.60 per share for Q2 2026, up from $0.55 in Q2 2025.
- Classified MWI Animal Health and U.S. Consulting Services as held for sale; U.S. Consulting Services divested April 30, 2026.
- Total assets increased to $81.65 billion as of March 31, 2026, from $76.59 billion on September 30, 2025.
- Net cash used in operating activities for six months was $(966.53) million, compared to $632.46 million provided in prior year.